Drug Patents owned by Strongbridge

1. List of Recorlev drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098877 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Jan, 2026

(2 years from now)

US10835530 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Jan, 2026

(2 years from now)

US10517868 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Jan, 2026

(2 years from now)

US9918984 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Jan, 2026

(2 years from now)

US11478471 STRONGBRIDGE NA
Jan, 2026

(2 years from now)

US11278547 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(16 years from now)

US11020393 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(16 years from now)

Do you want to check out RECORLEV patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 30, 2028

Drugs and Companies using LEVOKETOCONAZOLE ingredient

Market Authorisation Date: 30 December, 2021

Treatment: Treatment of endogenous hypercortisolemia in patients with cushing’s syndrome for whom surgery is not an option or has not been curative; During levoketoconazole dosage titration for the treatment of ...

Dosage: TABLET;ORAL

More Information on Dosage

RECORLEV family patents

13

United States

3

Korea, Republic of

2

Australia

2

Israel

2

Canada

2

Japan

2

China

2

European Union

IB

1

IB

1

New Zealand

1

Denmark

1

Spain

1

Austria

1

Cyprus

1

Portugal

1

Poland

1

Norway

1

Hong Kong

1

Slovenia

1

Mexico

1

South Africa

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in